Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
Le Coutre P, Kreuzer KA, Na IK, Schwarz M, Lupberger J, Holdhoff M, Baskaynak G, Gschaidmeier H, Platzbecker U, Ehninger G, Prejzner W, Huhn D, Schmidt CA. Le Coutre P, et al. Among authors: prejzner w. Am J Hematol. 2003 Aug;73(4):249-55. doi: 10.1002/ajh.10364. Am J Hematol. 2003. PMID: 12879428 Free article.
Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Lewandowski K, Warzocha K, Hellmann A, Skotnicki A, Prejzner W, Foryciarz K, Sacha T, Gniot M, Majewski M, Solarska I, Nowak G, Wasag B, Kobelski M, Scibiorski C, Siemiatkowski M, Lewandowska M, Komarnicki M. Lewandowski K, et al. Among authors: prejzner w. Pol Arch Med Wewn. 2009 Dec;119(12):789-94. Pol Arch Med Wewn. 2009. PMID: 20010464 Free article.
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Sacha T, Szczepanek E, Dumnicka P, Góra-Tybor J, Niesiobędzka-Krężel J, Prejzner W, Wasilewska E, Kłoczko J, Ciepłuch H, Makowska W, Patkowska E, Wasilewska J, Bober G, Kopera M, Wichary R, Kroll-Balcerzak R, Gromek T, Wach M, Rudkowska-Kazanowska A, Świniarska M, Paczkowska E, Biernat M, Joks M, Oller M, Kasza R, Kostyra A, Gil J, Grzybowska-Izydorczyk O. Sacha T, et al. Among authors: prejzner w. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):405-415. doi: 10.1016/j.clml.2021.11.012. Epub 2021 Nov 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34933827 Free article.
[No influence of imatinib on type 2 diabetes].
Chodorowski Z, Sein Anand J, Hellmann A, Prejzner W. Chodorowski Z, et al. Among authors: prejzner w. Przegl Lek. 2007;64(4-5):370-1. Przegl Lek. 2007. PMID: 17724918 Polish.
Imatinib therapy prior to myeloablative allogeneic stem cell transplantation.
Zaucha JM, Prejzner W, Giebel S, Gooley TA, Szatkowski D, Kałwak K, Wojnar J, Kruzel T, Balon J, Hołowiecki J, Hellmann A. Zaucha JM, et al. Among authors: prejzner w. Bone Marrow Transplant. 2005 Sep;36(5):417-24. doi: 10.1038/sj.bmt.1705087. Bone Marrow Transplant. 2005. PMID: 16007105 Clinical Trial.
34 results